AZIROC-250

AZIROC-250 is a pharmaceutical tablet formulation containing Azithromycin 250 mg, presented as an Azithromycin Tablets IP 250 mg formulation. Azithromycin is a macrolide antibiotic and the active pharmaceutical ingredient is clearly specified at a strength of 250 mg per tablet. The product is included within the Antibiotic segment of the Suprimeda pharmaceutical portfolio.

AZIROC-250 is formulated as an oral tablet, providing a standardized dosage form suitable for professional pharmaceutical cataloguing and institutional procurement. The formulation can be identified using key pharmaceutical terms such as Azithromycin 250 mg tablets, Azithromycin tablets, 250 mg antibiotic tablets and macrolide antibiotic formulation.

From a product identification and procurement perspective, AZIROC-250 provides a clearly defined active ingredient, pharmaceutical strength and dosage form. The product packaging specifies a 10 × 3 tablets configuration in a blister-pack format, making the pack specification straightforward for hospital and healthcare procurement teams.